Fig. 5From: Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute coronary syndrome: a systematic review and meta-analysisRisk of bias summary in included RCTs [15,16,17,18,19,20, 22, 24, 25]Back to article page
